Genomma Lab Internacional, S.A.B. de C.V. EBIT

Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX) currently reports a EBIT of $3.4B as of June 2026. That compares with $3.7B in the prior-year period — down 8.8% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Genomma Lab Internacional, S.A.B. de C.V.'s EBIT history and peer comparisons.

Genomma Lab Internacional, S.A.B. de C.V.'s EBIT decreased from $3.7B to $3.4B — a 8.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genomma Lab Internacional, S.A.B. de C.V.'s EBIT of $3.4B is lower than the its sector sector average of $2.6T. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Genomma Lab Internacional, S.A.B. de C.V. reported $3.4B in EBIT as of June 2026. That compares with $3.7B in the prior-year period — down 8.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $3.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Genomma Lab Internacional, S.A.B. de C.V., and consider following LABB.MX for alerts when major investors trade the stock.